GAMP is a framework, not a product classification The term “GAMP software” refers to computerised systems that fall within the scope of the GAMP 5 framework — the ISPE’s Good Automated Manufacturing Practice guide for validation of automated systems in pharmaceutical and regulated life sciences environments. GAMP is not a software standard, a certification mark, or a product label. It is a risk-based framework that pharmaceutical companies apply to determine appropriate validation activities for the software systems they use. Any software operating within GxP scope in a pharmaceutical environment is “GAMP software” in the sense that it should be classified, assessed, and validated using GAMP 5 principles. This includes enterprise systems (ERP, LIMS, MES), process control systems (SCADA, DCS), laboratory instruments with embedded software, custom applications, and increasingly, AI and machine learning systems. How GAMP 5 applies to modern software architectures The original GAMP 5 (2008) was designed for a world of monolithic, on-premise software installed and validated in a single environment. Modern pharmaceutical software increasingly uses architectures the original framework did not anticipate: Architecture GAMP 5 challenge Second Edition response Cloud/SaaS Validation responsibility shared between vendor and user Guidance on shared responsibility models, supplier qualification for cloud providers Microservices Multiple independent components, each potentially different categories Classify each component independently; validate interactions at integration points AI/ML Non-deterministic behaviour, continuous learning Continuous validation, performance monitoring, drift detection requirements Agile development Iterative releases conflict with traditional V-model Guidance on maintaining validation compliance across sprints and releases Containerised deployment Infrastructure abstraction complicates IQ Category 1 qualification extends to container runtime and orchestration The GAMP 5 Second Edition (2022) addresses each of these patterns, making it the first pharma software validation framework that explicitly covers modern development practices. The practical GAMP workflow For any new software system entering a pharmaceutical environment: Determine GxP relevance: Does the system affect product quality, patient safety, or data integrity? If no → GAMP does not apply. If yes → proceed. Classify the system: Assign GAMP software categories (1, 3, 4, 5) to each component. Modern systems often span multiple categories — the ML model is Category 5, the database is Category 1, the configured platform is Category 4. Assess risk: Determine the system’s risk to product quality and patient safety. High-risk systems require thorough validation. Lower-risk systems require proportionate effort. Define validation strategy: Document the validation approach — which activities, which documentation, which testing — based on classification and risk assessment. Apply critical thinking, not prescriptive checklists. Execute and document: Perform validation activities, document evidence, obtain approvals. Ensure traceability from requirements through test evidence. Maintain: Establish change control, periodic review, and ongoing monitoring processes that maintain the validated state throughout the system’s operational life. The detailed classification and validation approach for AI/ML systems under GAMP 5 provides specific guidance for the fastest-growing category of pharmaceutical software — systems that learn from data and change their behaviour over time. Why GAMP adoption matters for software vendors Software vendors selling to pharmaceutical companies should understand GAMP 5 because their customers’ validation teams will classify and validate the vendor’s product using this framework. Vendors that provide GAMP-aligned documentation — software category self-assessment, validation test scripts, audit trail specifications, configuration management documentation — reduce the validation burden on their pharmaceutical customers and accelerate procurement decisions. A vendor that cannot articulate their product’s GAMP category, describe their quality management system, or provide validation support documentation is creating work for their customer’s validation team — work that competing vendors with better regulatory awareness have already eliminated. How does the GAMP framework apply to SaaS and cloud-native systems? SaaS (Software as a Service) systems challenge the traditional GAMP validation model because the pharmaceutical company does not control the software deployment, update schedule, or infrastructure. The vendor may deploy updates weekly without the customer’s explicit approval — a practice that conflicts with GxP change control requirements. GAMP 5 Second Edition addresses this with guidance on managing SaaS validation. Our approach: validate the system at a specific version and configuration, monitor vendor change notifications, and assess each vendor update for GxP impact. High-impact changes (new features affecting regulated workflows, modified data structures, changed calculation methods) require re-validation. Low-impact changes (bug fixes, performance improvements, UI adjustments) require documented assessment but not re-validation. The vendor’s role in SaaS validation is providing the information that customers need: release notes with GxP impact assessment, validation documentation packages, audit reports (SOC 2, ISO 27001), and access to test environments for customer validation activities. We help pharmaceutical companies establish SaaS vendor management frameworks that satisfy regulatory requirements. The framework includes: vendor qualification (assessing the vendor’s quality system, development practices, and regulatory awareness), service level agreements (defining uptime, data integrity, and change notification requirements), and ongoing monitoring (tracking vendor changes, maintaining configuration documentation, and performing periodic vendor audits). This framework enables pharmaceutical companies to adopt modern SaaS solutions while maintaining the validation and change control discipline that regulators require.
